

We claim:

1. A candesartan cilexetil 1,4-dioxane solvate.
2. A candesartan cilexetil 1,4-dioxane solvate of claim 1, wherein the content of 1,4-dioxane is 8.8 to 13.0 % w/w.
- 5 3. A candesartan cilexetil 1,4-dioxane solvate of claim 1, characterized by an x-ray powder diffraction pattern having peaks expressed as  $2\theta$  at about 6.0, 10.7, 16.2, 18.0, 19.7, 20.6, 21.3, 21.7, and 22.3 degrees.
4. Candesartan cilexetil 1,4-dioxane solvate of claim 3, further characterized by an x-ray powder diffraction pattern as in figure 1.
- 10 5. A process for the preparation of candesartan cilexetil 1,4-dioxane solvate of claim 1, which comprises:
  - a) dissolving candesartan cilexetil in 1,4-dioxane; and
  - b) crystallizing candesartan cilexetil as 1,4-dioxane solvate from the solution at 5°C to 15°C.
- 15 6. A process according to claim 5, wherein candesartan cilexetil used is a crystalline or amorphous form of candesartan cilexetil.
7. A process according to claim 6, wherein the crystalline form of candesartan cilexetil is candesartan cilexetil form III.
8. A crystalline candesartan cilexetil form III, characterized by an x-ray powder diffraction pattern having peaks expressed as  $2\theta$  at about 6.3, 7.3, 8.1, 8.9,  
20 10.1, 14.6, 15.0, 15.8, and 18.8 degrees.
9. Candesartan cilexetil form III of claim 8, further characterized by an x-ray powder diffraction pattern as in figure 2.
10. A process for the preparation of candesartan cilexetil form III of claim 8,  
25 which comprises:
  - a) mixing candesartan cilexetil with toluene;
  - b) heating to obtain clear solution;
  - c) cooling slowly to 0°C to 5°C in about 1 hour;
  - d) maintaining at 0°C to 5°C for about 1 hour; and
  - 30 e) filtering the separated solid.
11. A process according to claim 10, wherein candesartan cilexetil used is candesartan cilexetil as 1,4-dioxane solvate of claim 1.

12. A crystalline candesartan cilexetil form IV, characterized by an x-ray powder diffraction pattern having peaks expressed as  $2\theta$  at about 6.1, 7.1, 11.6, 11.9, 17.9, 19.8 and 21.2 degrees.
13. Candesartan cilexetil form IV of claim 12, further characterized by an x-ray powder diffraction pattern as in figure 3.
14. A process for the preparation of candesartan cilexetil form IV of claim 12, which comprises:
- a) heating the mixture of candesartan cilexetil, methyl tert-butyl ether and methanol to 50°C to 55°C;
  - b) cooling to 20°C to 25°C;
  - c) maintaining at 20°C to 25°C for about 10 hours; and
  - d) separated crystals are collected by filtration.
15. A process according to claim 14, wherein candesartan cilexetil used is a crystalline or amorphous or dioxane solvated form of candesartan cilexetil.
16. A process according to claim 15, wherein candesartan cilexetil used is candesartan cilexetil 1,4-dioxane solvate of claim 1.
17. A process according to claim 15, wherein candesartan cilexetil used is candesartan cilexetil form III of claim 8.
18. A pharmaceutical composition comprising candesartan cilexetil form III of claim 8 or candesartan cilexetil form IV of claim 12 and a pharmaceutically acceptable carrier.
19. A pharmaceutical composition of claim 18, wherein candesartan cilexetil form III is used.
20. A pharmaceutical composition of claim 18, wherein candesartan cilexetil form IV is used.